Bone Metastasis Clinical Trial
Official title:
Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases - A Pilot Study
Verified date | August 2012 |
Source | Philips Healthcare |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
This study is to confirm the safety and technical of MRI guided High Intensity Focused
Ultrasound (HIFU) for Palliation for Pain of Skeletal Metastases.
MRI guided high intensity focused ultrasound uses ultrasound to heat and thermally ablate
tissue. The MRI system identifies the ultrasound path and monitors heat rise in the tissue.
The goal of the study is to show treatment safety and effectiveness. MR-guided HIFU will be
performed in patients who pass inclusion/exclusion criteria.
Status | Completed |
Enrollment | 10 |
Est. completion date | June 2012 |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age =18 years - Able to give informed consent - Weight <140kg - Radiologic evidence of bone metastases from any solid tumor - Able to characterize pain specifically at the site of interest (target lesion) - Pain score related to target lesion of =4 on a 0-10 point scale irrespective of medications - Target lesion accessible for MR-HIFU procedure - Target lesion maximum dimension =8cm - Target lesion is uncomplicated (i.e.: no fracture / spinal cord compression / cauda equina syndrome / soft tissue component) - Target lesion visible by non-contrast MRI - Interface between bone and skin lies =1cm from surface - Able to communicate sensation during MR-HIFU treatment - MR-HIFU treatment date =2 weeks from most recent treatment of primary tumor or any chemotherapy. Exclusion Criteria: - Prior radiotherapy / surgery / ablative therapy / other local therapy to target lesion. - Unable to characterize pain specifically at the site of interest (target lesion) - Pregnant / Nursing woman - Target lesion is complicated (i.e.: presence of one of fracture / spinal cord compression / cauda equina syndrome / soft tissue component). - Target lesion <1cm from nerve bundles / bladder / bowel - Target lesion in contact with hollow viscera - Target lesion located in skull, spine (excluding sacrum which is allowed) or sternum - Scar along proposed HIFU beam path - Orthopaedic implant along proposed HIFU beam path or at site of target lesion. - Serious cardiovascular, neurological, renal or hematological chronic disease - Active infection - Unable to tolerate required stationary position during treatment - Allergy to MRI contrast agent or sedation |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Sunnybrook Health Sciences Centre | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Philips Healthcare |
Canada,
Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol. 2002 Sep;64(3):275-80. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction of Pain Score | Determine the efficacy of MR-Guided HIFU in reducing pain scores related to the site treated as measured on the Brief Pain Inventory (BPI). | 90 Days | No |
Primary | Reduction of Pain Medication | Determine the efficacy of MR-Guided HIFU in reducing pain medication usage | 90 Days | No |
Primary | Complications and Adverse Events | Document complications and adverse events as well as the number of unintended lesions that occur as a result of treatment with MR-Guided HIFU. | 90 Days | Yes |
Secondary | Changes in bone density | Measure changes in bone density between X-ray and CT images taken prior to and following treatment. | 90 Days | No |
Secondary | Quality of Life | Measure patient quality of life using both the EORTC QLQ-BM22 and FACT-BP scales | 90 Days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01833806 -
A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
|
N/A | |
Terminated |
NCT01586273 -
Multicenter Study of Magnetic Resonance-guided High Intensity Focused Ultrasound for Pain Palliation of Bone Metastases
|
N/A | |
Completed |
NCT02609828 -
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
|
Phase 3 | |
Completed |
NCT04592887 -
Feasibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases
|
N/A | |
Recruiting |
NCT02231476 -
Efficacy of Radiotherapy in Combination With Zoledronic Acid on Pain Relief in Bone Metastasis Patients
|
Phase 2 | |
Recruiting |
NCT02426697 -
Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy
|
Phase 3 | |
Completed |
NCT00334139 -
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
|
Phase 4 | |
Completed |
NCT01784393 -
Chemoradiation for Bone Metastasis
|
Phase 2 | |
Terminated |
NCT02999152 -
Validation of Radio-induced Damage Biomarkers
|
N/A | |
Not yet recruiting |
NCT02480634 -
Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer
|
Phase 4 | |
Completed |
NCT02784652 -
Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors
|
Phase 2 | |
Completed |
NCT02673060 -
A Trial of MBC-11 in Patients With CIBD
|
Phase 1 | |
Completed |
NCT02774213 -
A Study to Collect Data About Analgesia in Patients With Bone Metastasis
|
||
Completed |
NCT02876731 -
Comparison of NaF PET-CT and Diffusion MRI in the Diagnosis of Bone Metastases (IMMETAOS)
|
N/A | |
Recruiting |
NCT02705157 -
The OPTIMAL Study - A Prospective Cohort of Patients With Bone Metastases of the Long Bones
|
N/A | |
Completed |
NCT01062503 -
Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC
|
N/A | |
Completed |
NCT00610272 -
Optimization of Radiotherapy in Treatment of Painful Bone Metastasis
|
Phase 3 | |
Completed |
NCT01998607 -
Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw
|
N/A | |
Recruiting |
NCT02876991 -
Evaluation of Sodium Fluoride PET in the Identification of Bone Metastases in Patients Having Undergone a Choline PET for Occult Recurrence of Prostatic Adenocarcinoma
|
N/A | |
Completed |
NCT02293642 -
Bone Pain Score Validation Initiative
|